SCHEMBL1642974

SCHEMBL1642974

C#Cc1ccnc(O)n1.c1cc2cc-2c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
APP P05067 1/20 0.34
MYC P01106 1/20 0.33
MAOB P27338 2/20 0.32
FDPS P14324 1/20 0.32
CLK4 Q9HAZ1 1/20 0.32
ABL1 P00519 1/20 0.32
ABCB1 P08183 1/20 0.32
BCR P11274 1/20 0.32
HSD17B1 P14061 6/20 0.31
HSD17B2 P37059 6/20 0.31
CYP3A4 P08684 2/20 0.31
CYP2C9 P11712 2/20 0.31
PLG P00747 1/20 0.31
F12 P00748 1/20 0.31
F11 P03951 1/20 0.31
KLKB1 P03952 1/20 0.31
PRSS1 P07477 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1644273 0.79 GRM4 (0.47) MEN1KMT2AMAOBMAP3K14
SCHEMBL2520704 0.79 BIRC5 (0.32) SYKMAP3K14
SCHEMBL13388231 0.78 KMO (0.50)
SCHEMBL14840581 0.76 MAP4K4 (0.40) SYK
SCHEMBL1644275 0.76 MAPK14 (0.42) MEN1KMT2ASYK
SCHEMBL1644268 0.73 NR1H2 (0.38) MEN1KMT2ACYP3A4CYP2C9SYK
SCHEMBL1476650 0.71 GRM5 (0.42) CLK4CYP1A2
SCHEMBL14840507 0.70 CNR2 (0.38) CYP3A4CYP2C9CYP1A2CYP2C19
SCHEMBL14840613 0.70 ADORA1 (0.48) MEN1KMT2ACYP3A4CYP2C9SYK
SCHEMBL1921796 0.70 MAP4K4 (0.40) LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2493856-B1 POSITIVE ALLOSTERIC MODULATORS (PAM) HOFFMANN LA ROCHE (CH) 2016-04-27 EP disclosed
US-8716316-B2 Positive allosteric modulators (PAM) HOFFMANN-LA ROCHE INC. (US) 2014-05-06 US disclosed
US-20130131056-A1 POSITIVE ALLOSTERIC MODULATORS (PAM) HOFFMANN-LA ROCHE INC. (US) 2013-05-23 US disclosed
US-8389536-B2 Positive allosteric modulators (PAM) HOFFMANN-LA ROCHE INC. (US) 2013-03-05 US disclosed
EP-2493856-A1 POSITIVE ALLOSTERIC MODULATORS (PAM) F. Hoffmann-La Roche AG (CH) 2012-09-05 EP disclosed
WO-2011051201-A1 POSITIVE ALLOSTERIC MODULATORS (PAM) F. HOFFMANN-LA ROCHE AG (CH) 2011-05-05 WO disclosed
US-20110098313-A1 POSITIVE ALLOSTERIC MODULATORS (PAM) HOFFMANN-LA ROCHE, INC. 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098313-A1 POSITIVE ALLOSTERIC MODULATORS (PAM) GRM5, GRM1, GRM2 ESR1 238/4885MEN1 4037/4885KMT2A 2147/4885
US-20130131056-A1 POSITIVE ALLOSTERIC MODULATORS (PAM) GRM5, GRM1, GRM2 ESR1 238/4885MEN1 4037/4885KMT2A 2147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.